Melanoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Melanoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ This clinical trial is focused on studying a type of skin cancer called metastatic or recurrent melanoma. The study is testing a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy involves using the patient’s own immune cells, specifically T cells, which are modified to better recognize and attack cancer cells. The study also involves a medication called nivolumab, which is known by the brand name OPDIVO. Nivolumab is a type of drug that helps the immune system fight cancer by blocking a protein that stops the immune system from attacking cancer cells.

The purpose of this study is to evaluate the safety and how well the treatment works when using ATL001 alone and in combination with nivolumab. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how the cancer responds to the treatment. The study aims to understand if this combination can help control the cancer and improve outcomes for patients with metastatic or recurrent melanoma.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study will also look at changes in the size of the tumor and overall survival rates. This research is important for developing new ways to treat melanoma and potentially improve the quality of life for those affected by this disease.

]]> Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ro7198457-and-pembrolizumab-for-patients-with-untreated-advanced-melanoma/ Wed, 29 Apr 2026 14:29:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ro7198457-and-pembrolizumab-for-patients-with-untreated-advanced-melanoma/ This clinical trial is focused on studying the treatment of Advanced Melanoma, a type of skin cancer that has spread to other parts of the body. The study is evaluating the effectiveness and safety of a new treatment combination. The treatment involves two medications: RO7198457, also known as Autogene Cevumeran, and Pembrolizumab, which is marketed under the name Keytruda. RO7198457 is a gene therapy product that uses mRNA technology, while Pembrolizumab is a type of protein-based medication that helps the immune system fight cancer.

The purpose of this study is to compare the combination of RO7198457 and Pembrolizumab against Pembrolizumab alone in patients who have not received prior treatment for their advanced melanoma. The study will monitor how long patients live without their cancer getting worse, known as progression-free survival. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the safety and effectiveness of the treatments will be closely observed.

Throughout the study, researchers will also look at other important factors, such as the overall survival of patients, the response of the cancer to the treatment, and any changes in the patients’ quality of life. Additionally, the study will track any side effects experienced by participants to ensure the treatments are safe. This trial aims to provide valuable information on whether the combination of RO7198457 and Pembrolizumab offers a better treatment option for patients with advanced melanoma compared to Pembrolizumab alone.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ Wed, 29 Apr 2026 14:28:56 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically when it has spread to other parts of the body or cannot be removed by surgery. The study is looking at patients with a specific genetic change known as the BRAF V600E/K mutation. The trial will test the effectiveness of a combination of medications: Encorafenib, Binimetinib, and Pembrolizumab. Encorafenib is taken as a capsule, Binimetinib as a tablet, and Pembrolizumab is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effects of the combination of Encorafenib, Binimetinib, and Pembrolizumab against a placebo combined with Pembrolizumab. Participants will be randomly assigned to receive either the combination of the three medications or the placebo with Pembrolizumab. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the melanoma.

This trial aims to determine if the combination of these medications can improve outcomes for patients with this specific type of melanoma. The study will also assess the safety of the medication combination and monitor any side effects that may occur. Participants will be closely observed by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s effectiveness.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ Wed, 29 Apr 2026 14:28:40 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically in patients who have a mutation known as BRAF V600E/K. This mutation can make the cancer more aggressive and harder to treat. The study is looking at patients whose melanoma has either spread to other parts of the body or cannot be removed by surgery. These patients have already been treated with a type of therapy called anti-PD-1 therapy, which helps the immune system fight cancer, but their cancer has continued to grow.

The purpose of the study is to compare two different treatment combinations to see which is more effective. One group of participants will receive a combination of three medications: encorafenib, binimetinib, and pembrolizumab. The other group will receive a combination of two medications: nivolumab and ipilimumab. These medications are given to help the immune system target and destroy cancer cells. Encorafenib and binimetinib are taken as tablets, while pembrolizumab, nivolumab, and ipilimumab are given through an infusion into a vein.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of time, during which participants will receive their assigned treatment and be monitored regularly by the study team. The goal is to see which treatment combination works better in controlling the cancer and improving the participants’ health. The study will also look at the safety of the treatments and any side effects that may occur. Participants will have regular check-ups and tests to track their progress and the effects of the treatment.

]]> Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors https://clinicaltrials.eu/trial/study-of-cobolimab-and-dostarlimab-for-children-and-young-adults-with-newly-diagnosed-or-relapsed-refractory-tumors/ Wed, 29 Apr 2026 14:22:51 +0000 https://clinicaltrials.eu/trial/study-of-cobolimab-and-dostarlimab-for-children-and-young-adults-with-newly-diagnosed-or-relapsed-refractory-tumors/ This clinical trial is focused on studying the effects of two medications, cobolimab and dostarlimab, in children and young adults who have been diagnosed with certain types of tumors. These tumors may have returned after treatment or have not responded to previous treatments. The study aims to understand how safe and tolerable these medications are when used together, as well as to determine the best dose for treatment. The trial will also explore how these medications work in the body and their ability to fight tumors.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.

]]>